These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 25287898

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 4. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
    Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K.
    Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Blood Pressure-Independent Effect of Olmesartan on Albuminuria in Mice Overexpressing Renin.
    Ichikawa H, Narita I, Narita M, Tanno T, Yokono Y, Kimura Y, Tanaka M, Osanai T, Okumura K, Tomita H.
    Int Heart J; 2018 Nov 28; 59(6):1445-1453. PubMed ID: 30369568
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov 28; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 9. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
    Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H.
    Hypertens Res; 2013 Dec 28; 36(12):1051-9. PubMed ID: 24026038
    [Abstract] [Full Text] [Related]

  • 10. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S, Ito M, Izuhara Y, Van Ypersele De Strihou C, Miyata T.
    Nephrology (Carlton); 2008 Dec 28; 13(6):517-21. PubMed ID: 18363646
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
    Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H.
    Kidney Blood Press Res; 2010 Dec 28; 33(3):213-20. PubMed ID: 20588058
    [Abstract] [Full Text] [Related]

  • 14. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.
    Igase M, Kohara K, Nagai T, Miki T, Ferrario CM.
    Hypertens Res; 2008 Mar 28; 31(3):553-9. PubMed ID: 18497476
    [Abstract] [Full Text] [Related]

  • 15. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M.
    Clin Pharmacol Ther; 2005 Nov 28; 78(5):501-7. PubMed ID: 16321616
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus.
    Liang Y, Deng H, Bi S, Cui Z, A L, Zheng D, Wang Y.
    Kidney Blood Press Res; 2015 Nov 28; 40(2):101-10. PubMed ID: 25791940
    [Abstract] [Full Text] [Related]

  • 18. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar 28; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.